Anavex Life Sciences Highlights Biomarker Data From Parkinson's Disease Dementia At International Conference
Anavex Life Sciences Corp (NASDAQ:AVXL) has announced the presentation of Phase 2 clinical biomarker data from the ANAVEX2-73-PDD-001 Parkinson's Disease Dementia (PDD) study at the AD/PD 2022 International Conference. MDS-UPDRS1 Total score improved significantly by -14.51 for patients treated with ANAVEX2-73 high oral once-daily dose compared to placebo. The improvement is clinically relevant,…
Benzinga ·
Benzinga
